$TGTX Q3 '25 Earnings Results & Recap
TG Therapeutics reported Q3 revenue of $161.7M, beating estimates of $152.11M, and EPS of $2.43, which includes a one-time, non-recurring $365 million tax benefit; adjusted EPS is closer to $0.20, with full year revenue guidance raised to $585M.